Devyser was awarded a tender in Italy for some of its oncology NGS solutions. The tender with the University Hospital of Bologna is valid for two years with the potential of a one-year…
Devyser was awarded a tender for its NGS product Devyser Thalassemia, which is used for screening and confirmation of thalassemia, a hereditary blood disorder. The tender with Instituto…
The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Tuesday, 14 May 2024 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed…
“Devyser reports continued strong sales growth and high gross margins for the quarter. It is particularly pleasing to see that our investment in the Americas is continuing to produce…
On Wednesday May 8 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2024 report (which will have been published earlier on May 8 at 07.30 a.m. CET).…
Devyser has received IVDR approval for Advyser Solid organs, its software for the post-transplant product One Lambda Devyser Accept cfDNA. This is Devyser’s first European approval for…
Devyser Diagnostics AB announces today it has entered into a co-marketing agreement with Hamilton Bonaduz AG, a leading global manufacturer of laboratory automation technology.
The…
Devyser Diagnostics AB announces today that it has received Medical Device Single Audit Program (MDSAP) certification for its quality management system (QMS) for both Devyser assays and…
Devyser´s annual report 2023 has today been published on the company´s website. The report is available on: https://investors.devyser.com/en/reports-presentations The financial year…
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be…
